Breaking News

Ligand, Spectrum Sign Global Supply Pact

March 14, 2013

Licenses melphalan product for development program

Ligand Pharmaceuticals has signed a global license and supply agreement with Spectrum Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan. Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestones, as well as royalties on future sales of Captisol-enabled melphalan.
 
The Captisol-enabled melphalan program is currently in development for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum will assume all development of the program under the license.
 
“We are pleased to have forged this agreement,” said John Higgins, president and chief executive officer of Ligand Pharmaceuticals. “Spectrum has an established oncology and hematology business, and this melphalan product is an ideal complement to their two commercial hematology products, Zevalin and Folotyn, including an expected high degree of commercial call overlap. Spectrum’s highly experienced, oncology-focused R&D team is committed to the efficient development of Captisol-enabled melphalan, and has established relationships with key investigators.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity